The MassARRAY-based OncoFOCUS panel (v3) was previously adopted in our community pathology lab as a fully validated clinical test of common mutations in BRAF, EGFR, KIT, KRAS, and NRAS genes, which are implicated in various cancers, particularly colon cancer, lung cancer and melanoma. This evidence concerns the gene KRAS and lung carcinoma.